Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | S100B | P04271 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16427245 | 0.82 | CTSS (0.38) | SYKCTSSMEN1KMT2AALK | |
| SCHEMBL17665103 | 0.82 | CTSS (0.42) | SYKMAPTMAPK1GAACTSS | |
| SCHEMBL17642662 | 0.82 | CTSS (0.40) | SYKCTSSALDH1A1L3MBTL1ALK | |
| SCHEMBL17265646 | 0.82 | MAPT (0.52) | LGMNMAPTMAPK1HTTGAA | |
| SCHEMBL24374737 | 0.80 | MAP3K12 (0.39) | ALK | |
| SCHEMBL17485376 | 0.79 | RORC (0.42) | CTSSKMT2AALKKITKDR | |
| SCHEMBL24904213 | 0.79 | TTK (0.44) | LGMNMAPTMAPK1HTTGAA | |
| SCHEMBL17660620 | 0.79 | RORC (0.40) | CTSSALDH1A1ALKKITKDR | |
| SCHEMBL12005505 | 0.78 | MAPT (0.52) | SYKMAPTMAPK1HTTGAA | |
| SCHEMBL520439 | 0.78 | LGMN (0.67) | LGMNMAPTMAPK1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | LGMN 3473/4885SYK 2358/4885MAPT 1451/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | LGMN 4672/4885SYK 2/4885MAPT 3636/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | LGMN 2917/4885SYK 3583/4885MAPT 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.